Wall Street analysts forecast that Alpine Immune Sciences Inc (NASDAQ:ALPN) will report sales of $310,000.00 for the current fiscal quarter, Zacks reports. Three analysts have made estimates for Alpine Immune Sciences’ earnings. The lowest sales estimate is $300,000.00 and the highest is $320,000.00. Alpine Immune Sciences posted sales of $130,000.00 in the same quarter last year, which would indicate a positive year-over-year growth rate of 138.5%. The firm is expected to report its next quarterly earnings results on Wednesday, March 27th.
On average, analysts expect that Alpine Immune Sciences will report full year sales of $940,000.00 for the current year, with estimates ranging from $710,000.00 to $1.02 million. For the next fiscal year, analysts forecast that the business will post sales of $1.15 million, with estimates ranging from $1.00 million to $1.26 million. Zacks Investment Research’s sales calculations are an average based on a survey of sell-side research firms that follow Alpine Immune Sciences.
Alpine Immune Sciences (NASDAQ:ALPN) last posted its quarterly earnings data on Thursday, November 8th. The biotechnology company reported ($0.88) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.57) by ($0.31). Alpine Immune Sciences had a negative return on equity of 43.25% and a negative net margin of 1,602.19%.
NASDAQ:ALPN traded down $0.03 during trading hours on Thursday, hitting $4.80. 4,571 shares of the stock were exchanged, compared to its average volume of 10,059. Alpine Immune Sciences has a twelve month low of $4.51 and a twelve month high of $11.75. The company has a quick ratio of 9.20, a current ratio of 9.20 and a debt-to-equity ratio of 0.05.
Several hedge funds have recently bought and sold shares of the company. Vanguard Group Inc. lifted its stake in shares of Alpine Immune Sciences by 5.2% in the 3rd quarter. Vanguard Group Inc. now owns 227,834 shares of the biotechnology company’s stock valued at $1,442,000 after purchasing an additional 11,200 shares during the period. Renaissance Technologies LLC lifted its stake in shares of Alpine Immune Sciences by 20.9% in the 2nd quarter. Renaissance Technologies LLC now owns 122,424 shares of the biotechnology company’s stock valued at $927,000 after purchasing an additional 21,124 shares during the period. Dimensional Fund Advisors LP lifted its stake in shares of Alpine Immune Sciences by 122.2% in the 2nd quarter. Dimensional Fund Advisors LP now owns 32,819 shares of the biotechnology company’s stock valued at $248,000 after purchasing an additional 18,052 shares during the period. Finally, DRW Securities LLC lifted its stake in shares of Alpine Immune Sciences by 138.7% in the 2nd quarter. DRW Securities LLC now owns 24,343 shares of the biotechnology company’s stock valued at $184,000 after purchasing an additional 14,143 shares during the period. 56.82% of the stock is currently owned by institutional investors.
Alpine Immune Sciences Company Profile
Alpine Immune Sciences, Inc focuses on the discovery and development of protein-based immunotherapies for the treatment of cancer, inflammatory disorders, and other diseases. Its lead programs include ALPN-101, an ICOS/CD28 antagonist program for the treatment of autoimmune and inflammatory diseases; and ALPN-202 program for the treatment of cancer.
Featured Story: Compound Annual Growth Rate (CAGR)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Alpine Immune Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alpine Immune Sciences and related companies with MarketBeat.com's FREE daily email newsletter.